Matrix metalloproteinases and their gene polymorphism in young ST-segment elevation myocardial infarction

Simple item page
dc.contributor.authorBasia, Deepaken_US
dc.contributor.authorGupta, Mohit Dayalen_US
dc.contributor.authorKunal, Shekharen_US
dc.contributor.authorMuheeb, Ghazien_US
dc.contributor.authorGirish, M.P.en_US
dc.contributor.authorBansal, Ankiten_US
dc.contributor.authorBatra, Vishalen_US
dc.contributor.authorYusuf, Jamalen_US
dc.contributor.authorMukhopadhyay, Saibalen_US
dc.contributor.authorTyagi, Sanjayen_US
dc.contributor.authorSingh, Rituen_US
dc.date.accessioned2023-07-21T11:36:57Z
dc.date.available2023-07-21T11:36:57Z
dc.date.issued2022-12
dc.description.abstractBackground: Genetic polymorphism in MMPs are associated with multiple adverse CV events. There is little evidence regarding role of MMPs and their genetic polymorphisms in young (<50 years) STsegment elevation myocardial infarction (STEMI) patients. Methods: This study included 100 young (18e50 years) STEMI patients and 100 healthy controls. Serum levels of MMP-3, MMP-9 and TIMP were estimated for both patients as well as controls. Additionally, genetic polymorphisms in the MMP-9 gene (_x0001_1562 C/T and R279Q) & MMP-3 gene (5A/6A-1612) was evaluated. All these patients were followed up for one year and major adverse cardiac events (MACE) were determined. Results: Serum levels of MMP-3 (128.16 ± 115.81 vs 102.3 ± 57.28 ng/mL; P ¼ 0.04), MMP-9 (469.63 ± 238.4 vs 188.88 ± 94.08 pg/mL; P < 0.0001) and TIMP (5.84 ± 1.93 vs 2.28 ± 1.42 ng/mL; P < 0.0001) were significantly higher in patients as compared to controls. Additionally, patients with genetic polymorphisms in the MMP genes (5A/5A, 6A/6A and the AG genotypes) had an increased risk of STEMI. Patients with MACE had significantly higher levels of MMP-9 (581.73 ± 260.93 vs 438.01 ± 223.38 pg/mL; P ¼ 0.012). A cutoff value of 375.5 pg/mL of MMP-9 was best able to discriminate patients with STEMI and MACE with sensitivity of 77.3% and specificity of 57%. Conclusion: Novel biomarkers such as MMP-3, MMP-9 and TIMP and their genetic polymorphism are associated with the susceptibility for STEMI in young individuals. Higher MMP-9 levels in STEMI patients with MACE suggests its potential role in predicting cardiac remodeling and left ventricular dysfunctionen_US
dc.identifier.affiliationsDepartment of Cardiology, Govind Ballabh Pant Institute of Post Graduate Medical Education and Research, Delhi, Indiaen_US
dc.identifier.affiliationsDepartment of Cardiology, ESIC Medical College and Hospital, Faridabad, Haryana, Indiaen_US
dc.identifier.affiliationsDepartment of Biochemistry, Lady Hardinge Medical College & Hospital, Indiaen_US
dc.identifier.citationBasia Deepak, Gupta Mohit Dayal, Kunal Shekhar, Muheeb Ghazi, Girish M.P., Bansal Ankit, Batra Vishal, Yusuf Jamal, Mukhopadhyay Saibal, Tyagi Sanjay, Singh Ritu. Matrix metalloproteinases and their gene polymorphism in young ST-segment elevation myocardial infarction. Indian Heart Journal. 2022 Dec; 74(6): 519-523en_US
dc.identifier.issn0019-4832
dc.identifier.issn2213-3763
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/220957
dc.languageenen_US
dc.publisherCardiological Society of Indiaen_US
dc.relation.issuenumber6en_US
dc.relation.volume74en_US
dc.source.urihttps://doi.org/10.1016/j.ihj.2022.11.001en_US
dc.subjectAcute coronary syndromeen_US
dc.subjectAlleleen_US
dc.subjectGene polymorphismen_US
dc.subjectSTEMIen_US
dc.titleMatrix metalloproteinases and their gene polymorphism in young ST-segment elevation myocardial infarctionen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
IHJ2022v74n6p519.pdf
Size:
419.81 KB
Format:
Adobe Portable Document Format
Download
Collections
Indian Heart Journal